Demyelinating Autoimmune Diseases, CNS: Clinical Trials

3,687 trials for Demyelinating Autoimmune Diseases, CNS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2031 completed, 513 unknown, 400 recruiting, 251 terminated. 1325 Not applicable, 511 Phase 2, 340 Phase 3, 315 Phase 1, 226 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable1325Completed 719, Unknown 242, Recruiting 160, Not yet recruiting 70, Active not recruiting 55, Terminated 40, Withdrawn 19, Enrolling by invitation 17, Suspended 3
Phase 2511Completed 278, Terminated 74, Recruiting 49, Unknown 43, Withdrawn 27, Active not recruiting 21, Not yet recruiting 14, Enrolling by invitation 4, Suspended 1
Phase 3340Completed 203, Terminated 46, Active not recruiting 29, Unknown 23, Recruiting 22, Withdrawn 12, Not yet recruiting 4, Suspended 1
Phase 1315Completed 173, Recruiting 37, Terminated 35, Unknown 26, Not yet recruiting 14, Active not recruiting 13, Withdrawn 13, Enrolling by invitation 2, Suspended 2
Phase 4226Completed 134, Terminated 35, Unknown 20, Withdrawn 13, Recruiting 10, Active not recruiting 9, Not yet recruiting 3, Enrolling by invitation 2
Early Phase 137Completed 11, Recruiting 8, Not yet recruiting 6, Unknown 5, Withdrawn 3, Suspended 2, Active not recruiting 1, Terminated 1

Follow Demyelinating Autoimmune Diseases, CNS: new trials by email Literature Review of Demyelinating Autoimmune Diseases, CNS trials Research Report on Demyelinating Autoimmune Diseases, CNS

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis
Body-weight supported treadmill training in a room cooled to 16°C - Multiple Sclerosis, Neurological Rehabilitation
Not applicableWithdrawnMemorial University of Newfoundland2030-01-012024-11-27
Inductive Therapeutic Exercise in Multiple Sclerosis
Experimental: Inductive Therapeutic Exercise (ETI), Control: Sham Inductive Therapeutic Exercise (sham-ETI) - Multiple Sclerosis
Not applicableNot yet recruitingFundación San Juan De Dios302027-10-012026-10-02
Exploring Reproductive Decision-Making Among Women With Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingAssiut University2722027-06-012026-09-21
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
Phase 2Not yet recruitingMoein Amin202027-03-012026-08-19
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Phase 1 / Phase 2Not yet recruitingAbelZeta Inc.1192027-02-012026-10-13
Exercise With and Without Cognitive Training
Effect of Exercise with and Without Cognitive Training on Gait - Multiple Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development302027-01-042026-03-03
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle
Phase 2WithdrawnMichael, Levy M.D.,Ph.D.2026-12-312025-07-16
Lead Exposure and Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingAssiut University1402026-12-302026-02-20
Local Vibration and Ankle Mobilization in Multiple Sclerosis
Local Vibration, Ankle Joint Mobilization - Multiple Sclerosis
Not applicableNot yet recruitingGaziantep Islam Science and Technology University602026-12-152026-10-19
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)
Phase 1Not yet recruitingImviva Bio812026-12-012026-08-24
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
Cohort - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Not yet recruitingLuxembourg Institute of Health1002026-12-012026-09-22
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2Not yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis
Autologous haemopoietic stem cell transplantation - Multiple Sclerosis
Not applicableNot yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
Behavioural intervention for physical activity for multiple sclerosis (BIPAMS) - Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Not applicableNot yet recruitingUniversity of Alabama at Birmingham302026-12-012025-12-22
[18F]F-DED PET Imaging of Reactive Astrocytes in Multiple Sclerosis
[18F]fluorodeprenyl-D2 - Multiple Sclerosis
Not applicableNot yet recruitingParc de Salut Mar302026-12-012026-09-04
Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care
MS Boost, Standard of care - Multiple Sclerosis, Fatigue Syndrome, Chronic
Not applicableNot yet recruitingAd scientiam2082026-12-012025-10-03
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
Online wellness course and online exercise platform, Usual Care Group - Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Not applicableNot yet recruitingUniversity of Iowa1182026-11-152026-09-28
The Effects of High-Intensity Interval Training on Gait, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis
Moderate-Intensity Continuous Training (MICT), High-Intensity Interval Training (HIIT) - Multiple Sclerosis, High-intensity Interval Training
Not applicableNot yet recruitingHacettepe University402026-11-012026-09-23
Driving Performance in Parkinson's Disease and Multiple Sclerosis Using a Driving Simulator
Standardized Driving Simulator Assessment - Parkinson, Multiple Sclerosis
Not yet recruitingUniversity Hospital Olomouc1002026-11-012026-09-09
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09

Showing 20 of 3687. Sign in to see all of them.

Narrower conditions

Multiple Sclerosis (3146)  ·  Multiple Sclerosis, Relapsing-Remitting (612)  ·  Multiple Sclerosis, Chronic Progressive (242)  ·  Fatigue (210)  ·  Neuromyelitis Optica (171)  ·  Motor Activity (170)  ·  Stroke (105)  ·  Parkinson Disease (97)  ·  Muscle Spasticity (76)  ·  Cognitive Dysfunction (75)  ·  Demyelinating Diseases (73)  ·  Spinal Cord Injuries (72)  ·  Autoimmune Diseases (70)  ·  Depression (70)  ·  Nervous System Diseases (59)

Broader conditions

Immune System Diseases (3668)  ·  Autoimmune Diseases of the Nervous System (3642)  ·  Nervous System Diseases (3628)  ·  Autoimmune Diseases (3617)  ·  Demyelinating Diseases (3614)  ·  Pathological Conditions, Signs and Symptoms (946)  ·  Signs and Symptoms (543)  ·  Pathologic Processes (456)  ·  Multiple Sclerosis (401)  ·  Disease Attributes (379)  ·  Central Nervous System Diseases (325)  ·  Chronic Disease (303)  ·  Behavior (291)  ·  Neurologic Manifestations (272)

Interventions

Interferon beta-1a (106)  ·  ocrelizumab (82)  ·  Dimethyl Fumarate (70)  ·  Exercise (70)  ·  Natalizumab (66)  ·  Interferon beta-1b (64)  ·  Fingolimod Hydrochloride (57)  ·  Glatiramer Acetate (55)  ·  teriflunomide (40)  ·  Methylprednisolone (38)  ·  Rituximab (37)  ·  Blood Specimen Collection (35)  ·  4-Aminopyridine (33)  ·  ofatumumab (33)  ·  Alemtuzumab (30)

Sponsors

Biogen (160)  ·  Novartis Pharmaceuticals (92)  ·  Merck KGaA, Darmstadt, Germany (49)  ·  Bayer (47)  ·  Hoffmann-La Roche (39)  ·  Hasselt University (34)  ·  Johns Hopkins University (32)  ·  Kessler Foundation (32)  ·  Assiut University (30)  ·  Fondazione Don Carlo Gnocchi ETS (30)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (30)  ·  Sanofi (30)  ·  University of Washington (28)  ·  Gazi University (27)  ·  NYU Langone Health (26)

Countries

United States (1335)  ·  France (427)  ·  Italy (340)  ·  Turkey (Türkiye) (324)  ·  Germany (313)  ·  Canada (295)  ·  United Kingdom (295)  ·  Spain (264)  ·  Poland (184)  ·  Belgium (179)  ·  Czechia (164)  ·  Switzerland (160)  ·  Russia (125)  ·  Netherlands (116)  ·  Denmark (115)

Top investigators

Daniel S Reich, M.D. (11)  ·  Cagla Ozkul (9)  ·  Michael Levy, MD, PhD (9)  ·  Peter Feys, prof. dr. (9)  ·  Eric Thouvenot (8)

Results publications

PMID 31072380, PMID 21387374, PMID 33023488, PMID 32447743, PMID 34882037, PMID 23669008, PMID 25475413, PMID 27411694, PMID 27733070, PMID 29275977, PMID 30918100, PMID 31654272, PMID 31762387, PMID 32710396, PMID 36163349, PMID 37652990, PMID 37745914, PMID 39935588, PMID 40258203, PMID 40756531, PMID 40966534, PMID 42328798, PMID 6685237, PMID 12525714, PMID 22622860, PMID 23531349, PMID 24131282, PMID 25245812, PMID 26932146, PMID 28002679, PMID 28002688, PMID 28825348, PMID 30144037, PMID 31675266, PMID 32426039, PMID 32539719, PMID 33414927, PMID 34035833, PMID 34376508, PMID 34378446, PMID 35003076, PMID 36619856, PMID 37272540, PMID 39251561, PMID 40743487, PMID 42368888, PMID 42624921, PMID 7613530, PMID 10022678, PMID 11955556

NIH funding

2014 (21), 2023 (21), 2015 (20), 2019 (15), 2016 (14), 2018 (14), 2017 (13), 2009 (12), 2008 (11), 2025 (8), 2005 (5), 2004 (3), K23AT004433 (2), K24AT012644 (2), P30DK056336 (2)